Drug intelligence / Profile preview

Nimvec

Development stage: Preclinical
Lead developer: Amarna Therapeutics
Modality: Gene Addition/Replacement → Gene Therapies, Gene Editing → Gene Therapies, Gene Silencing → Gene Therapies
Administration: Intravenous

Overview

Nimvec is a patented gene therapy platform developed by Amarna Therapeutics. It is being assessed in collaboration with Phenocell for the treatment of Dry Age-Related Macular Degeneration (Dry AMD). The platform's efficacy and mode-of-action are being validated in a 3-dimensional iPSC-derived retinal model, with the ultimate goal of developing a curative treatment for Dry AMD.

Brand names: Nimvec

Beyond the preview

Go deeper on Nimvec.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nimvec.

Explore the full profile